Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Sep. 30, 2018 | Oct. 31, 2018 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Sep. 30, 2018 | |
Document Fiscal Year Focus | 2,019 | |
Document Fiscal Period Focus | Q1 | |
Trading Symbol | AGTC | |
Entity Registrant Name | APPLIED GENETIC TECHNOLOGIES CORP | |
Entity Central Index Key | 1,273,636 | |
Current Fiscal Year End Date | --06-30 | |
Entity Filer Category | Accelerated Filer | |
Entity Smaller Company | true | |
Entity Emerging Growth Company | true | |
Entity Transition Period | true | |
Entity Common Stock, Shares Outstanding | 18,133,993 |
Condensed Balance Sheets (Unaud
Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2018 | Jun. 30, 2018 |
Current assets: | ||
Cash and cash equivalents | $ 26,472 | $ 31,065 |
Investments | 78,968 | 73,840 |
Grants receivable | 219 | 210 |
Prepaid and other current assets | 2,527 | 4,009 |
Total current assets | 108,186 | 109,124 |
Property and equipment, net | 5,016 | 5,254 |
Intangible assets, net | 949 | 968 |
Investment in Bionic Sight | 1,972 | 1,980 |
Other assets | 1,205 | 1,206 |
Total assets | 117,328 | 118,532 |
Current liabilities: | ||
Accounts payable | 3,029 | 945 |
Accrued and other liabilities | 5,677 | 7,155 |
Deferred revenue | 16,319 | 6,295 |
Total current liabilities | 25,025 | 14,395 |
Deferred revenue, net of current portion | 9,106 | 610 |
Other liabilities | 4,258 | 4,345 |
Total liabilities | 38,389 | 19,350 |
Stockholders' equity: | ||
Preferred stock, par value $.001 per share, 5,000 shares authorized; no shares issued and outstanding | ||
Common stock, par value $.001 per share, 150,000 shares authorized; 18,143 and 18,137 shares issued; 18,130 and 18,126 shares outstanding at September 30, and June 30, 2018, respectively | 18 | 18 |
Additional paid-in capital | 211,320 | 210,139 |
Shares held in treasury of: 13 and 11 at September 30, 2018 and June 30, 2018 respectively | (57) | (49) |
Accumulated deficit | (132,342) | (110,926) |
Total stockholders' equity | 78,939 | 99,182 |
Total liabilities and stockholders' equity | $ 117,328 | $ 118,532 |
Condensed Balance Sheets (Una_2
Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Sep. 30, 2018 | Jun. 30, 2018 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 150,000,000 | 150,000,000 |
Common stock, shares issued | 18,143,000 | 18,137,000 |
Common stock, shares outstanding | 18,130,000 | 18,126,000 |
Treasury stock, shares held | 13,000 | 11,000 |
Condensed Statements of Operati
Condensed Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Sep. 30, 2018 | Sep. 30, 2017 | |
Revenue: | ||
Total revenue | $ 14,034 | $ 10,315 |
Operating expenses: | ||
Research and development | 10,065 | 8,276 |
General and administrative and other | 3,213 | 3,706 |
Total operating expenses | 13,278 | 11,982 |
Income (loss) from operations | 756 | (1,667) |
Other income: | ||
Investment income, net | 471 | 270 |
Total other income, net | 471 | 270 |
Income (loss) before provision for income taxes and equity in net losses of affiliate | 1,227 | (1,397) |
Provision for income taxes | 19 | |
Income (loss) before equity in net losses of affiliate | 1,208 | (1,397) |
Equity in net losses of affiliate | (8) | |
Net income (loss) | $ 1,200 | $ (1,397) |
Weighted Average Shares Outstanding | ||
Weighted average shares outstanding - basic | 18,128 | 18,088 |
Weighted average shares outstanding - diluted | 18,158 | 18,088 |
Net income (loss) per common share | ||
Net income (loss) per share, basic | $ 0.07 | $ (0.08) |
Net income (loss) per share, diluted | $ 0.07 | $ (0.08) |
Collaboration [Member] | ||
Revenue: | ||
Total revenue | $ 14,025 | $ 10,308 |
Grant and Other [Member] | ||
Revenue: | ||
Total revenue | $ 9 | $ 7 |
Condensed Statement of Stockhol
Condensed Statement of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands | Total | Common Stock [Member] | Treasury Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] |
Beginning balance at Jun. 30, 2017 | $ 115,329 | $ 18 | $ 204,937 | $ (89,626) | |
Beginning balance, shares at Jun. 30, 2017 | 18,088,000 | ||||
Share based compensation expense | 1,469 | 1,469 | |||
Shares issued under employee plans | 2 | $ 2 | |||
Shares issued under employee plans, shares | 5,000 | ||||
Net income (loss) | $ (1,397) | $ (1,397) | |||
Beginning balance at Sep. 30, 2017 | $ 18,093 | ||||
Ending balance at Sep. 30, 2017 | 115,403,000 | 18,000 | 206,408,000 | (91,023,000) | |
Beginning balance at Jun. 30, 2018 | $ 99,182 | $ 18 | $ (49) | $ 210,139 | $ (110,926) |
Beginning balance, shares at Jun. 30, 2018 | 18,126,000 | 11,000 | |||
Cumulative impact of adopting Topic 606 on July 1, 2018 | (22,616) | (22,616) | |||
Share based compensation expense | 1,181 | 1,181 | |||
Shares issued under employee plans | (8) | $ (8) | |||
Shares issued under employee plans, shares | 4,000 | 2,000 | |||
Net income (loss) | 1,200 | 1,200 | |||
Beginning balance at Sep. 30, 2018 | $ 78,939 | $ 18 | $ (57) | $ 211,320 | $ (132,342) |
Ending balance at Sep. 30, 2018 | 18,130,000 | 13,000 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Sep. 30, 2018 | Sep. 30, 2017 | |
Cash flows from operating activities | ||
Net income (loss) | $ 1,200 | $ (1,397) |
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
Share-based compensation expense | 1,181 | 1,469 |
Depreciation and amortization | 321 | 234 |
Recovery of bad debts | (369) | |
Investment premium accretion | (142) | 82 |
Equity in net losses of affiliate | 8 | |
Changes in operating assets and liabilities: | ||
Grants receivable | (9) | (8) |
Prepaid and other assets | 723 | (8) |
Deferred revenues | (2,967) | (9,754) |
Accounts payable | 2,084 | 1,470 |
Accrued and other liabilities | (1,447) | (739) |
Net cash provided by (used in) operating activities | 583 | (8,651) |
Cash flows from investing activities | ||
Purchase of property and equipment | (41) | (130) |
Purchase of and capitalized costs related to intangible assets | (23) | |
Maturities of investments | 24,736 | 26,807 |
Purchases of investments | (29,722) | |
Net cash (used in) provided by investing activities | (5,050) | 26,677 |
Cash flows from financing activities | ||
Proceeds from exercise of common stock options | 2 | |
Deferred offering costs | (113) | |
Payments made toward capital lease obligations | (13) | |
Net cash (used in) provided by financing activities | (126) | 2 |
Net change in cash and cash equivalents | (4,593) | 18,028 |
Cash and cash equivalents, beginning of period | 31,065 | 30,706 |
Cash and cash equivalents, end of period | 26,472 | 48,734 |
Supplemental disclosure of cash flow information | ||
Cash paid during the period for income taxes | $ 670 | |
Shares issued for no consideration | $ 8 |
Organization and Operations
Organization and Operations | 3 Months Ended |
Sep. 30, 2018 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Operations | 1. Organization and Operations: Applied Genetic Technologies Corporation (the “Company” or “AGTC”) was incorporated as a Florida corporation on January 19, 1999 and reincorporated as a Delaware corporation on October 24, 2003. The Company is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. In July 2015, the Company entered into a collaboration agreement (the “Collaboration Agreement”) with Biogen MA, Inc., a wholly owned subsidiary of Biogen Inc. (“Biogen”), pursuant to which the Company and Biogen will collaborate to develop, seek regulatory approval for and commercialize gene therapy products to treat X-linked X-linked The Company has devoted substantially all of its efforts to research and development, including clinical trials. The Company has not completed the development of any products. The Company has generated revenue from collaboration agreements, sponsored research payments and grants, but has not generated product revenue to date and is subject to a number of risks similar to those of other early stage companies in the biotechnology industry, including dependence on key individuals, the difficulties inherent in the development of commercially viable products, the need to obtain additional capital necessary to fund the development of its products, development by the Company or its competitors of technological innovations, risks of failure of clinical studies, protection of proprietary technology, compliance with government regulations and ability to transition to large-scale production of products. As of September 30, 2018, the Company had an accumulated deficit of $132.3 million. While the Company expects to continue to generate some revenue from partnering, including under the collaboration with Biogen, the Company expects to incur losses for the foreseeable future. The Company has funded its operations to date primarily through public offerings of its common stock, private placements of its preferred stock, and collaborations. At September 30, 2018, the Company had cash and cash equivalents and liquid investments of $105.4 million. |
Summary of Significant Accounti
Summary of Significant Accounting Policies: | 3 Months Ended |
Sep. 30, 2018 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies: | 2. Summary of Significant Accounting Policies: Basis of presentation The accompanying unaudited condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and, in the opinion of management, include all adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows for each period presented. The adjustments referred to above are of a normal and recurring nature. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to U.S. Securities and Exchange Commission (“SEC”) rules and regulations for interim reporting. The Condensed Balance Sheet as of June 30, 2018 was derived from audited financial statements, but does not include all disclosures required by GAAP. These Unaudited Condensed Financial Statements should be read in conjunction with the audited financial statements included in the Company’s 2018 Annual Report on Form 10-K, 10-K”). Segment reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, we have viewed our operations and managed our business as one segment. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Cash and cash equivalents Cash consists of funds held in bank accounts. Cash equivalents consist of short-term, highly liquid investments with original maturities of 90 days or less at the time of purchase and generally include money market accounts. Investments The Company’s investments consist of certificates of deposit and debt securities classified as held-to held-to-maturity maturity. Held-to-maturity held-to-maturity The Company uses the specific identification method to determine the cost basis of securities sold. Investments are considered to be impaired when a decline in fair value is judged to be other-than-temporary. The Company evaluates an investment for impairment by considering the length of time and extent to which market value has been less than cost or amortized cost, the financial condition and near-term prospects of the issuer as well as specific events or circumstances that may influence the operations of the issuer and the Company’s intent to sell the security or the likelihood that it will be required to sell the security before recovery of the entire amortized cost. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded to investment income (expense) and a new cost basis in the investment is established. Fair value of financial instruments The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and unobservable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Revenue recognition Effective July 1, 2018, the Company adopted the provisions of ASC Topic 606, Revenue from Contracts with Customers, The adoption of the new revenue recognition guidance resulted in an increase of $22.6 million in deferred revenue and accumulated deficit as of July 1, 2018. For the three months ended September 30, 2018, revenue increased by $1.5 million, net income increased by $1.5 million and basic and diluted net income per share increased by $0.08 per share based on revenue recognition under Topic 606 as compared to the Company’s prior revenue recognition methodology under ASC 605, Revenue Recognition The Company may enter into collaboration agreements which are within the scope of Topic 606, under which the Company licenses rights to its technology and certain of the Company’s product candidates and performs research and development services for third parties. The terms of these arrangements typically may include payment of one or more of the following: non-refundable, up-front Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of the contract; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer. Performance obligations are promises to transfer distinct goods or services to the customer. Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised good or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include both fixed consideration or variable consideration. At the inception of an arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount to be received based on which method better predicts the amount expected to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. The Company will assess its revenue generating arrangements in order to determine whether a significant financing component exists and conclude that a significant financing component does not exist in any of its arrangements if: (a) the promised consideration approximates the cash selling price of the promised goods and services or any significant difference is due to factors other than financing; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract. The Company’s contracts will often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the customer’s control, such as regulatory approvals, are not included in the transaction price. At the end of each subsequent reporting period, the Company re-evaluates catch-up For arrangements that may include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company’s collaboration arrangements. The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation. For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front non-refundable, up-front The Company receives payments from its customers based on billing terms established in each contract. Such billings generally have 30-day Income taxes The Company uses the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Tax Cut and Jobs Act (the “Tax Act”) was enacted on December 22, 2017. The Tax Act contains several key provisions including, among other things, reducing the U.S. federal corporate tax rate from 35% to 21%. In addition, federal net operating losses (“NOLs”) will be carried forward indefinitely, but will be subject to an 80% utilization against taxable income. The Company follows the guidance in SEC Staff Accounting Bulletin 118 (SAB 118) which provides additional clarification regarding the application of ASC Topic 740 in situations where the Company does not have the necessary information available, prepared, or analyzed in reasonable detail to complete the accounting for certain income tax effects of the Act for the reporting period in which the Act was enacted. SAB 118 provides for a measurement period beginning in the reporting period that includes the Act’s enactment date and ending when the Company has obtained, prepared, and analyzed the information needed in order to complete the accounting requirements but in no circumstances should the measurement period extend beyond one year from the enactment date. The Company has enacted the reduction in tax rate effective January 1, 2018, which resulted in a decrease to the deferred tax asset and a decrease to the valuation allowance. The Company is in the process of evaluating the Tax Act changes in section 162(m), Internal Revenue Code of 1986, regarding deductions for excessive employee compensation. The Company continues to gather and analyze information, including the definition of an employee contract for stock grants not vested as of the enactment date of the Act. It is the intention of the Company to complete the necessary analysis within the measurement period however the Company anticipates that any adjustment would be a decrease to deferred tax asset and valuation allowance with no impact to income tax expense. As required by U.S. GAAP, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not For the three months ended September 30, 2018, the Company’s tax expense included an increase in the uncertain tax position liability of $18,919 related to interest on the uncertain tax position. The uncertain tax position liability as of September 30, 2018 and June 30, 2018 was $1,977,919 and $1,959,000, respectively. Research and development Research and development costs include costs incurred in identifying, developing and testing product candidates and generally comprise compensation and related benefits and non-cash pre-clinical As part of the process of preparing its financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for services for which the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company’s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to it at that time. The significant estimates in the Company’s accrued research and development expenses are related to expenses incurred with respect to academic research centers, contract research organizations, and other vendors in connection with research and development activities for which it has not yet been invoiced. There may be instances in which the Company’s service providers require advance payments at the inception of a contract or in which payments made to these vendors will exceed the level of services provided, resulting in a prepayment of the research and development expense. Such prepayments are charged to research and development expense as and when the service is provided or when a specific milestone outlined in the contract is reached. Prepayments related to research and development activities were $1.0 million and $1.0 million at September 30, 2018 and June 30, 2018, respectively, and are included within the prepaid and other current assets line item on the unaudited condensed balance sheets. Share-based compensation The Company accounts for share-based awards issued to employees in accordance with ASC Topic 718, Compensation—Stock Compensation non-employees 505-50, Equity-Based Payments to Non-employees 505-50”). 505-50, non-employees re-measurement For purposes of calculating stock-based compensation, the Company estimates the fair value of stock options using a Black-Scholes option-pricing model. The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the Company’s stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. Historically, the expected volatility was primarily based on the historical volatility of peer company data. For the three months ended September 30, 2018, the expected volatility is based on the historical volatility of the company stock price. If the Company had used peer company data for the three months ended September 30, 2018, share-based compensation expense for the quarter would have differed by an insignificant amount. The expected life of the stock options is based on historical and other economic data trended into the future. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the Company’s stock options. The dividend yield assumption is based on the Company’s history and expectation of no dividend payouts. If factors change and the Company employs different assumptions, stock-based compensation expense may differ significantly from what has been recorded in the past. If there is a difference between the assumptions used in determining stock-based compensation expense and the actual factors which become known over time, specifically with respect to anticipated forfeitures, the Company may change the input factors used in determining stock-based compensation costs for future grants. These changes, if any, may materially impact the Company’s results of operations in the period such changes are made. Net income (loss) per share Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net income (loss) per share calculations, stock options and warrants are considered to be common stock equivalents if they are dilutive. For the three-month period ended September 30, 2018, stock options and warrants were dilutive and increased common stock equivalents outstanding by 29,744 shares. For the three-month period ending September 30, 2017, basic and diluted net loss per share are the same due to stock options and warrants being considered anti-dilutive. If stock options and warrants had been dilutive, their impact would have increased common stock equivalents outstanding at September 30, 2017 by 0.2 million shares. Comprehensive income (loss) Comprehensive income (loss) consists of net income (loss) and changes in equity during a period from transactions and other equity and circumstances generated from non-owner New Accounting Pronouncements In May 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-09, Scope of Modification Accounting Compensation – Stock Compensation In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) right-of-use In May 2014, Topic 606, which replaces the existing accounting standards for revenue recognition with a single comprehensive five-step model. The core principle is to recognize revenue upon the transfer of goods or services to customers at an amount that reflects the consideration expected to be received. It also requires enhanced disclosures about revenue, provides guidance for transactions that were not previously addressed comprehensively, and improves guidance for multiple-element arrangements. The guidance applies to any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. Since its issuance, the FASB has amended several aspects of the new guidance, including provisions that address revenue recognition associated with the licensing of intellectual property. In July 2015, the FASB delayed the effective date of this guidance by one year. The guidance is effective for public companies for annual periods beginning after December 15, 2017 as well as interim periods within those annual periods using either the full retrospective approach or modified retrospective approach. The Company adopted the new standard effective July 1, 2018 using the modified retrospective approach. Refer to Note 6 for the impact of adoption. |
Share-based Compensation Plans
Share-based Compensation Plans | 3 Months Ended |
Sep. 30, 2018 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Share-based Compensation Plans | 3. Share-based Compensation Plans: The Company uses stock options and awards of restricted stock to provide long-term incentives for its employees, non-employee For the Three Months Ended September 30, 2018 2017 (In thousands, except per share amounts) Shares Weighted Shares Weighted Outstanding at June 30, 3,107 $ 10.93 2,714 $ 12.96 Granted 863 4.31 715 4.88 Exercised — — (5 ) 0.35 Forfeited (166 ) 8.08 (290 ) 9.98 Expired (9 ) 14.95 (4 ) 17.80 Outstanding at September 30, 3,795 $ 9.54 3,130 $ 11.40 Exercisable at September 30, 2,092 1,691 Weighted average fair value of options granted during the period $ 2.81 $ 3.52 For the three months ended September 30, 2018, share-based compensation expense related to stock options awarded to employees, non-employee As of September 30, 2018, there was $7.0 million of unrecognized compensation expense related to non-vested non-employee Assumption Three months ended September 30, 2018 Three months Dividend yield 0.00% 0.00% Expected term 6.00 to 6.25 years 6.25 years Risk-free interest rate 2.77% to 2.99% 1.83% to 1.97% Expected Volatility 69.22% 83.53% |
Investments
Investments | 3 Months Ended |
Sep. 30, 2018 | |
Investments Schedule [Abstract] | |
Investments | 4. Investments: Cash in excess of immediate requirements is invested in accordance with the Company’s investment policy that primarily seeks to maintain adequate liquidity and preserve capital. The following table summarizes the Company’s investments by category as of September 30, 2018 and June 30, 2018: In thousands September 30, June 30, Investments - Current: Certificates of deposit $ 1,869 $ 2,106 Debt securities - held-to-maturity 77,099 71,734 Total investments - current $ 78,968 $ 73,840 A summary of the Company’s debt securities classified as held-to-maturity September 30, 2018 In thousands Amortized Gross Gross Fair Investments - Current: U.S. government and agency obligations $ 77,099 $ — $ (77 ) $ 77,022 Total investments - current $ 77,099 $ — $ (77 ) $ 77,022 June 30, 2018 In thousands Amortized Gross Gross Fair Investments - Current: U.S. government and agency obligations $ 69,731 $ — $ (60 ) $ 69,671 Corporate obligations 2,003 — (1 ) 2,002 $ 71,734 $ — $ (61 ) $ 71,673 The amortized cost and fair value of held-to-maturity In thousands Amortized Fair Value Due in one year or less $ 77,099 $ 77,022 $ 77,099 $ 77,022 The Company believes that the unrealized losses disclosed above were primarily driven by interest rate changes rather than by unfavorable changes in the credit ratings associated with these securities and as a result, the Company continues to expect to collect the principal and interest due on its debt securities that have an amortized cost in excess of fair value. At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, noting neither a significant deterioration since purchase nor other factors leading to an other-than-temporary impairment. Therefore, the Company believes these losses to be temporary. As of September 30, 2018, the Company did not have the intent to sell any of the securities that were in an unrealized loss position at that date. |
Fair Value of Financial Instrum
Fair Value of Financial Instruments and Investments | 3 Months Ended |
Sep. 30, 2018 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments and Investments | 5. Fair Value of Financial Instruments and Investments: Certain assets and liabilities are measured at fair value in the Company’s financial statements or have fair values disclosed in the notes to the financial statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability. The following methods and assumptions were used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument included in the table below. Cash and Cash Equivalents. Certificates of Deposit. Debt securities – held-to-maturity. held-to-maturity The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis: In thousands Quoted prices Significant (Level 2) Significant (Level 3) Total Fair Total September 30, 2018 Cash and cash equivalents $ 26,472 — — $ 26,472 $ 26,472 Certificates of deposit — 1,868 — 1,868 1,869 Held-to-maturity Corporate obligations — — — — — U.S. government and agency obligations 77,022 — — 77,022 77,099 Total assets $ 103,494 $ 1,868 $ — $ 105,362 $ 105,440 June 30, 2018 Cash and cash equivalents $ 31,065 $ — $ — $ 31,065 $ 31,065 Certificates of deposit — 2,100 — 2,100 2,106 Held-to-maturity Corporate obligations — 2,002 — 2,002 2,003 U.S. government and agency obligations 69,671 — — 69,671 69,731 Total assets $ 100,736 $ 4,102 $ — $ 104,838 $ 104,905 |
Collaboration Agreement
Collaboration Agreement | 3 Months Ended |
Sep. 30, 2018 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Collaboration Agreement | 6. Collaboration Agreement Biogen On July 1, 2015, the Company entered into a Collaboration Agreement (the “Collaboration Agreement”), a Manufacturing License and Technology Transfer Agreement (the “Manufacturing Agreement”), and the Common Stock Purchase Agreement (the “Equity Agreement”) with Biogen (collectively, the “Biogen Agreement”), pursuant to which the Company and Biogen will collaborate to develop, seek regulatory approval for and commercialize gene therapy products to treat XLRS, XLRP, and discovery programs targeting three indications based on the Company’s adeno-associated virus vector technologies. Under the Collaboration Agreement, the Company has granted to Biogen with respect to the XLRS and XLRP programs, and upon exercise of the option for the applicable discovery program, an exclusive, royalty-bearing license, with the right to grant sublicenses, to use adeno-associated virus vector technology and other technology controlled by the Company for the licensed products or discovery programs developed under the Collaboration Agreements. Biogen and the Company have also granted each other worldwide licenses, with the right to grant sublicenses, of their respective interests in other intellectual property developed under the collaboration outside the licensed products or discovery programs. Biogen has pre-funded the Company to conduct all development activities through the completion of a first in human trial for the XLRS program and all development activities through the date that the Investigational New Drug Application (“IND”) becomes effective and the completion of a natural history study for the XLRP program. In addition, Biogen has pre-funded the Company to conduct discovery, research and development activities for additional drug candidates through the stage of clinical candidate designation for discovery programs targeting three indications (of which one indication has two development plans at contract inception), after which, Biogen may exercise an option to continue to develop, seek regulatory approval for and commercialize the designated clinical candidate. The pre-funded research and development activities for each program are referred to as “Pre-Funded Activities”. Biogen will reimburse the Company on an FTE basis for any additional development activities that it requests the Company to perform (“Post-Funded Activities”). In February 2016, the Company announced Biogen’s selection of adrenoleukodystrophy as the non-ophthalmic indication of the discovery programs. Under the terms of the Collaboration Agreement, the Company, in part through its participation in joint committees with Biogen, will participate in overseeing the development and commercialization of these specific programs. Pursuant to the Manufacturing Agreement, Biogen may elect an option to receive a manufacturing license for up to six genes for a fixed fee per gene elected. If exercised, the Company becomes eligible to receive certain event milestones and royalties. Under the Collaboration Agreement, the Company was paid an upfront nonrefundable fee of $94.0 million of which $58.4 million related to the Pre-Funded Activities (“Pre-Funded Amounts”) and $35.6 million related to the access of licenses. In addition, under the terms of the Equity Agreement, Biogen purchased 1,453,957 shares of the Company’s common stock at a price of $20.63 per share, for an aggregate cash purchase price of $30.0 million. The shares issued to Biogen represented approximately 8.1% of the Company’s outstanding common stock on a post-issuance basis, calculated on the number of shares that were outstanding at June 30, 2015, and constitute restricted securities that may not be resold by Biogen other than in a transaction registered under, or pursuant to an exemption from the registration requirements of, the Securities Act of 1933, as amended. The Company is also eligible to receive total payments of up to $472.5 million based on the successful achievement of future milestones under its XLRS and XLRP programs. For XLRS, the Company is eligible to receive up to: (i) $45.0 million in milestone payments based upon the successful achievement of clinical milestones (relating to dosing in specified trials), (ii) $155.0 million in milestone payments based upon the achievement of regulatory approvals and first commercial sale in specified territories and (iii) $65.0 million in milestone payments based upon the achievement of worldwide sales targets. For the XLRS program, the Company has an option to share development costs and profits after the initial clinical trial data are available instead of receiving milestone payments. For XLRP, the Company is eligible to receive up to: (i) $42.5 million in milestone payments based upon successful achievement of clinical milestones (relating to dosing in specified trials), (ii) $102.5 million in milestone payments based upon the achievement of regulatory approvals and first commercial sale in specified territories and (iii) $62.5 million in milestone payments based upon the achievement of worldwide sales targets. For the XLRP program, the Company has an option to share development costs and profits after the initial clinical trial data are available instead of receiving milestone payments. In addition, the Company is eligible to receive payments of up to $592.5 million based on the exercise of the option for and the successful achievement of future milestones under its discovery programs. Each discovery program is categorized as Category A, Category B or Category C depending on the nature of the indication it seeks to address. For Category A, the Company is eligible to receive payments of up to: (i) $20.0 million based upon the successful achievement of clinical milestones (relating to dosing in specified trials) and (ii) $70.0 million in milestone payments based upon the achievement of regulatory approvals and first commercial sale in specified territories. For Category B, the Company is eligible to receive payments of up to: (i) $27.5 million based upon the successful achievement of clinical milestones (relating to dosing in specified trials) and (ii) $105.0 million in milestone payments based upon the achievement of regulatory approvals and first commercial sale in specified territories. For Category C, the Company is eligible to receive payments of up to: (i) $40.0 million based upon the successful achievement of clinical milestones (relating to dosing in specified trials) and (ii) $140.0 million in milestone payments based upon the achievement of regulatory approvals and first commercial sale in specified territories. Under certain limited circumstances, if there are discovery products from more than one discovery program in any of Category A, Category B or Category C, then the milestone payments under the applicable category shall be payable for the applicable discovery product from each such discovery program to achieve the specified milestones. Biogen will also pay revenue-based royalties for each licensed product at tiered rates ranging from high-single digit to mid-teen percentages of annual net sales of the XLRS or XLRP products and at rates ranging from mid-single digit to low-teen percentages of annual net sales for the discovery products. Prior to 2018, the Company received a $5.0 million milestone payment related to initial dosing of a XLRS patient. In April 2018, the Company triggered a $2.5 million milestone payment related to the initial dosing of a XLRP patient. In July 2018, the Company triggered a $10.0 million milestone payment related to the treatment of a first patient of second cohort in a Phase 1/2 Clinical XLRP Study. Accounting Analysis For the periods prior to July 1, 2018, the Company applied the provisions of ASC 605 in accounting for this arrangement. Refer to the Company’s Annual Report on Form 10-K for the year ended June 30, 2018, filed with the Securities and Exchange Commission on September 11, 2018, for the accounting analysis under these provisions. Under ASC 605 and Topic 606, the Company has concluded that the Collaboration Agreement, the Manufacturing Agreement and the Equity Agreement should be accounted for as one arrangement as the agreements were with the same party and were negotiated and executed contemporaneously. The performance obligations and the allocated transaction price as of the date of initial application of Topic 606 are as follows (in thousands): Performance Obligations: Allocated Transaction Price XLRS License and Pre-Funded $ 52,060 XLRP License and Pre-Funded 43,570 Pre-Funded 16,700 $ 112,330 The Pre-Funded Pre-Funded Pre-Funded The Company concluded that Post-Funded Activities represent customer options that are not material rights as any services requested by Biogen and provided by the Company are reimbursed at a rate that reflects the estimated standalone selling price for the services. As such, the Company will recognize revenue related to Post-Funded Activities as the services are provided. Through the date of adoption of ASC 606, the Company has recognized revenue of $4.7 million for Post-Funded Activities. The Company recorded revenue of $1.1 million in the three months period ended September 30, 2018 related to Post-Funded Activities. The Company concluded that the option to receive i) commercial licenses for the Discovery Programs that achieve clinical candidate designation, as defined in the Collaboration Agreement and ii) manufacturing licenses for up to six genes pursuant to the Manufacturing Agreement represent customer options that are not material rights as the exercise price for such options reflects the estimated standalone selling price for such option. As such, the Company will account for such option if and when the options are exercised. As of the date of the initial application of Topic 606, the total transaction price for the Biogen Agreement was $112.3 million which included a $5.0 million milestone payment for initiation of dosing of XLRS and a $2.5 million milestone payment for initiation of dosing of XLRP. The Company used the most-likely method to determine the amount of variable consideration in the Biogen Agreement. The Company believes that any estimated amount of variable consideration related to clinical and regulatory milestone payments should be fully constrained as the achievement of such milestones is highly susceptible to factors outside of the Company’s control. The Company has determined that the commercial milestones and sales-based royalties will be recognized when the related sales occur as they were deemed to relate predominately to the license granted and therefore have also been excluded from the transaction price. The Company will re-evaluate In the quarter ended September 30, 2018, the Company received a $10.0 million milestone payment related to XLRP which increased the transaction price. Based on an understanding between the parties in the quarter ended September 30, 2018, the Company also reallocated $1.1 million of Pre-Funded Pre-Funded catch-up Summary of Contract Assets and Liabilities The transaction price was allocated to the performance obligations based on the relative estimated standalone selling price of each performance obligation or, in the case of certain variable consideration, to one or more performance obligations. The estimated standalone selling prices for performance obligations, that include a license and Pre-Funded Pre-Funded The Company will recognize revenue related to the performance obligations which include a license and Pre-Funded During the three months ended September 30, 2018 and 2017, the Company recorded revenue of $14.0 million, and $10.3 million, respectively, related to its efforts under the Biogen Agreement. The Company has accounts receivable balances with Biogen as of September 30, 2018 and June 30, 2018 of $0.7 million and $1.7 million, respectively, related to the Biogen Agreement. As of September 30, 2018, the Company had recorded $25.4 million in deferred revenue related to the Biogen Agreement that will be recognized over the remaining performance period. The Company expects to satisfy its remaining performance obligations under the Biogen Agreement within the next three years. The company’s revenue is comprised of the following related to the Biogen Agreement: For the three months 2018 2017 Collaboration revenue Licenses and related services $ 4,619 $ 9,754 Development services 1,058 554 Milestone revenue 8,348 — Total collaboration revenue $ 14,025 $ 10,308 License and related services revenue is comprised of revenue related to the Company’s completion of performance obligations that contain the delivery of licenses and Pre-Funded Activities. Development services revenue relates to the delivery of Post Funded Activities. Milestone revenue relates to the portion of milestone payments received that are recognized as revenue based on the proportional performance of the underlying performance obligation. Summary of Contract Assets and Liabilities The following table presents changes in the balances of our contract assets and liabilities during the three months ended September 30, 2018 (in thousands): Balance at Additions Deductions Balance at Three months ended September 30, 2018 Contract assets $ — $ — $ — $ — Contract liabilities: Deferred revenue $ 29,521 $ 10,000 $ 14,096 $ 25,425 The Company recorded an entry to increase deferred revenue and accumulated deficit for $22.6 million as of July 1, 2018 related to the adoption of Topic 606. The impact of the adoption of Topic 606 is reflected within the beginning of period balance. Additions include the $10.0 million milestone payment received associated with the XLRP program. Deductions from deferred revenue include revenue recognized related to the deferred revenue balance at the beginning of the period of $4.6 million, revenue recognized related to additions to deferred revenue in the quarter of $8.3 million (of which $7.8 million relates to performance in prior quarters) and $1.1 million of variable consideration that was constrained in the quarter. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies: (Policies) | 3 Months Ended |
Sep. 30, 2018 | |
Accounting Policies [Abstract] | |
Basis of presentation | Basis of presentation The accompanying unaudited condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and, in the opinion of management, include all adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows for each period presented. The adjustments referred to above are of a normal and recurring nature. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to U.S. Securities and Exchange Commission (“SEC”) rules and regulations for interim reporting. The Condensed Balance Sheet as of June 30, 2018 was derived from audited financial statements, but does not include all disclosures required by GAAP. These Unaudited Condensed Financial Statements should be read in conjunction with the audited financial statements included in the Company’s 2018 Annual Report on Form 10-K, 10-K”). |
Segment reporting | Segment reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, we have viewed our operations and managed our business as one segment. |
Use of estimates | Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates. |
Cash and cash equivalents | Cash and cash equivalents Cash consists of funds held in bank accounts. Cash equivalents consist of short-term, highly liquid investments with original maturities of 90 days or less at the time of purchase and generally include money market accounts. |
Investments | Investments The Company’s investments consist of certificates of deposit and debt securities classified as held-to held-to-maturity maturity. Held-to-maturity held-to-maturity The Company uses the specific identification method to determine the cost basis of securities sold. Investments are considered to be impaired when a decline in fair value is judged to be other-than-temporary. The Company evaluates an investment for impairment by considering the length of time and extent to which market value has been less than cost or amortized cost, the financial condition and near-term prospects of the issuer as well as specific events or circumstances that may influence the operations of the issuer and the Company’s intent to sell the security or the likelihood that it will be required to sell the security before recovery of the entire amortized cost. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded to investment income (expense) and a new cost basis in the investment is established. |
Fair value of financial instruments | Fair value of financial instruments The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and unobservable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. |
Revenue recognition | Revenue recognition Effective July 1, 2018, the Company adopted the provisions of ASC Topic 606, Revenue from Contracts with Customers, The adoption of the new revenue recognition guidance resulted in an increase of $22.6 million in deferred revenue and accumulated deficit as of July 1, 2018. For the three months ended September 30, 2018, revenue increased by $1.5 million, net income increased by $1.5 million and basic and diluted net income per share increased by $0.08 per share based on revenue recognition under Topic 606 as compared to the Company’s prior revenue recognition methodology under ASC 605, Revenue Recognition The Company may enter into collaboration agreements which are within the scope of Topic 606, under which the Company licenses rights to its technology and certain of the Company’s product candidates and performs research and development services for third parties. The terms of these arrangements typically may include payment of one or more of the following: non-refundable, up-front Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of the contract; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer. Performance obligations are promises to transfer distinct goods or services to the customer. Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised good or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include both fixed consideration or variable consideration. At the inception of an arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount to be received based on which method better predicts the amount expected to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. The Company will assess its revenue generating arrangements in order to determine whether a significant financing component exists and conclude that a significant financing component does not exist in any of its arrangements if: (a) the promised consideration approximates the cash selling price of the promised goods and services or any significant difference is due to factors other than financing; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract. The Company’s contracts will often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the customer’s control, such as regulatory approvals, are not included in the transaction price. At the end of each subsequent reporting period, the Company re-evaluates catch-up For arrangements that may include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company’s collaboration arrangements. The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation. For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front non-refundable, up-front The Company receives payments from its customers based on billing terms established in each contract. Such billings generally have 30-day |
Income taxes | Income taxes The Company uses the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Tax Cut and Jobs Act (the “Tax Act”) was enacted on December 22, 2017. The Tax Act contains several key provisions including, among other things, reducing the U.S. federal corporate tax rate from 35% to 21%. In addition, federal net operating losses (“NOLs”) will be carried forward indefinitely, but will be subject to an 80% utilization against taxable income. The Company follows the guidance in SEC Staff Accounting Bulletin 118 (SAB 118) which provides additional clarification regarding the application of ASC Topic 740 in situations where the Company does not have the necessary information available, prepared, or analyzed in reasonable detail to complete the accounting for certain income tax effects of the Act for the reporting period in which the Act was enacted. SAB 118 provides for a measurement period beginning in the reporting period that includes the Act’s enactment date and ending when the Company has obtained, prepared, and analyzed the information needed in order to complete the accounting requirements but in no circumstances should the measurement period extend beyond one year from the enactment date. The Company has enacted the reduction in tax rate effective January 1, 2018, which resulted in a decrease to the deferred tax asset and a decrease to the valuation allowance. The Company is in the process of evaluating the Tax Act changes in section 162(m), Internal Revenue Code of 1986, regarding deductions for excessive employee compensation. The Company continues to gather and analyze information, including the definition of an employee contract for stock grants not vested as of the enactment date of the Act. It is the intention of the Company to complete the necessary analysis within the measurement period however the Company anticipates that any adjustment would be a decrease to deferred tax asset and valuation allowance with no impact to income tax expense. As required by U.S. GAAP, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not For the three months ended September 30, 2018, the Company’s tax expense included an increase in the uncertain tax position liability of $18,919 related to interest on the uncertain tax position. The uncertain tax position liability as of September 30, 2018 and June 30, 2018 was $1,977,919 and $1,959,000, respectively. |
Research and development | Research and development Research and development costs include costs incurred in identifying, developing and testing product candidates and generally comprise compensation and related benefits and non-cash pre-clinical As part of the process of preparing its financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for services for which the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company’s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to it at that time. The significant estimates in the Company’s accrued research and development expenses are related to expenses incurred with respect to academic research centers, contract research organizations, and other vendors in connection with research and development activities for which it has not yet been invoiced. There may be instances in which the Company’s service providers require advance payments at the inception of a contract or in which payments made to these vendors will exceed the level of services provided, resulting in a prepayment of the research and development expense. Such prepayments are charged to research and development expense as and when the service is provided or when a specific milestone outlined in the contract is reached. Prepayments related to research and development activities were $1.0 million and $1.0 million at September 30, 2018 and June 30, 2018, respectively, and are included within the prepaid and other current assets line item on the unaudited condensed balance sheets. |
Share-based compensation | Share-based compensation The Company accounts for share-based awards issued to employees in accordance with ASC Topic 718, Compensation—Stock Compensation non-employees 505-50, Equity-Based Payments to Non-employees 505-50”). 505-50, non-employees re-measurement For purposes of calculating stock-based compensation, the Company estimates the fair value of stock options using a Black-Scholes option-pricing model. The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the Company’s stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. Historically, the expected volatility was primarily based on the historical volatility of peer company data. For the three months ended September 30, 2018, the expected volatility is based on the historical volatility of the company stock price. If the Company had used peer company data for the three months ended September 30, 2018, share-based compensation expense for the quarter would have differed by an insignificant amount. The expected life of the stock options is based on historical and other economic data trended into the future. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the Company’s stock options. The dividend yield assumption is based on the Company’s history and expectation of no dividend payouts. If factors change and the Company employs different assumptions, stock-based compensation expense may differ significantly from what has been recorded in the past. If there is a difference between the assumptions used in determining stock-based compensation expense and the actual factors which become known over time, specifically with respect to anticipated forfeitures, the Company may change the input factors used in determining stock-based compensation costs for future grants. These changes, if any, may materially impact the Company’s results of operations in the period such changes are made. |
Net income (loss) per share | Net income (loss) per share Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net income (loss) per share calculations, stock options and warrants are considered to be common stock equivalents if they are dilutive. For the three-month period ended September 30, 2018, stock options and warrants were dilutive and increased common stock equivalents outstanding by 29,744 shares. For the three-month period ending September 30, 2017, basic and diluted net loss per share are the same due to stock options and warrants being considered anti-dilutive. If stock options and warrants had been dilutive, their impact would have increased common stock equivalents outstanding at September 30, 2017 by 0.2 million shares. |
Comprehensive income (loss) | Comprehensive income (loss) Comprehensive income (loss) consists of net income (loss) and changes in equity during a period from transactions and other equity and circumstances generated from non-owner |
New Accounting Pronouncements | New Accounting Pronouncements In May 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-09, Scope of Modification Accounting Compensation – Stock Compensation In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) right-of-use In May 2014, Topic 606, which replaces the existing accounting standards for revenue recognition with a single comprehensive five-step model. The core principle is to recognize revenue upon the transfer of goods or services to customers at an amount that reflects the consideration expected to be received. It also requires enhanced disclosures about revenue, provides guidance for transactions that were not previously addressed comprehensively, and improves guidance for multiple-element arrangements. The guidance applies to any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. Since its issuance, the FASB has amended several aspects of the new guidance, including provisions that address revenue recognition associated with the licensing of intellectual property. In July 2015, the FASB delayed the effective date of this guidance by one year. The guidance is effective for public companies for annual periods beginning after December 15, 2017 as well as interim periods within those annual periods using either the full retrospective approach or modified retrospective approach. The Company adopted the new standard effective July 1, 2018 using the modified retrospective approach. Refer to Note 6 for the impact of adoption. |
Certificates of Deposit | Certificates of Deposit. |
Debt securities - held-to-maturity | Debt securities – held-to-maturity. held-to-maturity |
Share-based Compensation Plans
Share-based Compensation Plans (Tables) | 3 Months Ended |
Sep. 30, 2018 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Summary of Stock Option Activity | A summary of the stock option activity for the three months ended September 30, 2018 and 2017 is as follows: For the Three Months Ended September 30, 2018 2017 (In thousands, except per share amounts) Shares Weighted Shares Weighted Outstanding at June 30, 3,107 $ 10.93 2,714 $ 12.96 Granted 863 4.31 715 4.88 Exercised — — (5 ) 0.35 Forfeited (166 ) 8.08 (290 ) 9.98 Expired (9 ) 14.95 (4 ) 17.80 Outstanding at September 30, 3,795 $ 9.54 3,130 $ 11.40 Exercisable at September 30, 2,092 1,691 Weighted average fair value of options granted during the period $ 2.81 $ 3.52 |
Stock Option Pricing Model Assumption | The following assumptions were made in estimating fair value: Assumption Three months ended September 30, 2018 Three months Dividend yield 0.00% 0.00% Expected term 6.00 to 6.25 years 6.25 years Risk-free interest rate 2.77% to 2.99% 1.83% to 1.97% Expected Volatility 69.22% 83.53% |
Investments (Tables)
Investments (Tables) | 3 Months Ended |
Sep. 30, 2018 | |
Investments Schedule [Abstract] | |
Summary of Company's Investments | The following table summarizes the Company’s investments by category as of September 30, 2018 and June 30, 2018: In thousands September 30, June 30, Investments - Current: Certificates of deposit $ 1,869 $ 2,106 Debt securities - held-to-maturity 77,099 71,734 Total investments - current $ 78,968 $ 73,840 |
Summary of Company's Debt Securities Held-to-Maturity | A summary of the Company’s debt securities classified as held-to-maturity September 30, 2018 In thousands Amortized Gross Gross Fair Investments - Current: U.S. government and agency obligations $ 77,099 $ — $ (77 ) $ 77,022 Total investments - current $ 77,099 $ — $ (77 ) $ 77,022 June 30, 2018 In thousands Amortized Gross Gross Fair Investments - Current: U.S. government and agency obligations $ 69,731 $ — $ (60 ) $ 69,671 Corporate obligations 2,003 — (1 ) 2,002 $ 71,734 $ — $ (61 ) $ 71,673 |
Summary of Amortized Cost and Fair Value of Held-to-Maturity Debt Securities | The amortized cost and fair value of held-to-maturity In thousands Amortized Fair Value Due in one year or less $ 77,099 $ 77,022 $ 77,099 $ 77,022 |
Fair Value of Financial Instr_2
Fair Value of Financial Instruments and Investments (Tables) | 3 Months Ended |
Sep. 30, 2018 | |
Fair Value Disclosures [Abstract] | |
Schedule of Major Category of Company's Financial Assets and Liabilities Measured at Fair Value on Recurring Basis | The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis: In thousands Quoted prices Significant (Level 2) Significant (Level 3) Total Fair Total September 30, 2018 Cash and cash equivalents $ 26,472 — — $ 26,472 $ 26,472 Certificates of deposit — 1,868 — 1,868 1,869 Held-to-maturity Corporate obligations — — — — — U.S. government and agency obligations 77,022 — — 77,022 77,099 Total assets $ 103,494 $ 1,868 $ — $ 105,362 $ 105,440 June 30, 2018 Cash and cash equivalents $ 31,065 $ — $ — $ 31,065 $ 31,065 Certificates of deposit — 2,100 — 2,100 2,106 Held-to-maturity Corporate obligations — 2,002 — 2,002 2,003 U.S. government and agency obligations 69,671 — — 69,671 69,731 Total assets $ 100,736 $ 4,102 $ — $ 104,838 $ 104,905 |
Collaboration Agreement (Tables
Collaboration Agreement (Tables) | 3 Months Ended |
Sep. 30, 2018 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Summary of Performance Obligations and Transaction Price | The performance obligations and the allocated transaction price as of the date of initial application of Topic 606 are as follows (in thousands): Performance Obligations: Allocated Transaction Price XLRS License and Pre-Funded $ 52,060 XLRP License and Pre-Funded 43,570 Pre-Funded 16,700 $ 112,330 |
Components of Collaboration Revenue | The company’s revenue is comprised of the following related to the Biogen Agreement: For the three months 2018 2017 Collaboration revenue Licenses and related services $ 4,619 $ 9,754 Development services 1,058 554 Milestone revenue 8,348 — Total collaboration revenue $ 14,025 $ 10,308 |
Summary of Changes in Contract Assets and Contract Liabilities | The following table presents changes in the balances of our contract assets and liabilities during the three months ended September 30, 2018 (in thousands): Balance at Additions Deductions Balance at Three months ended September 30, 2018 Contract assets $ — $ — $ — $ — Contract liabilities: Deferred revenue $ 29,521 $ 10,000 $ 14,096 $ 25,425 |
Organization and Operations - A
Organization and Operations - Additional Information (Detail) $ in Thousands | Jul. 01, 2015TargetIndication | Jul. 31, 2015TargetIndication | Sep. 30, 2018USD ($) | Jun. 30, 2018USD ($) |
Summary Of Organization And Operations [Line Items] | ||||
Accumulated deficit | $ (132,342) | $ (110,926) | ||
Cash and cash equivalents and liquid investments | $ 105,400 | |||
Collaboration Agreement [Member] | BIOGEN [Member] | ||||
Summary Of Organization And Operations [Line Items] | ||||
Number of target indications | TargetIndication | 3 | 3 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies - Additional Information (Detail) | 3 Months Ended | 6 Months Ended | |||
Sep. 30, 2018USD ($)Segment$ / sharesshares | Sep. 30, 2017shares | Dec. 31, 2017 | Jul. 01, 2018USD ($) | Jun. 30, 2018USD ($) | |
Summary of Significant Accounting Policies [Line Items] | |||||
Number of operating segments | Segment | 1 | ||||
Federal statutory income tax rate | 21.00% | 35.00% | |||
Utilization of taxable income | 80.00% | ||||
Increase in uncertain tax position liability | $ 18,919 | ||||
Uncertain tax position liability | $ 1,977,919 | $ 1,959,000 | |||
Dilutive impact of stock options and warrants | shares | 29,744 | 200,000 | |||
Prepaid and Other Current Assets [Member] | |||||
Summary of Significant Accounting Policies [Line Items] | |||||
Advance payments | $ 1,000,000 | $ 1,000,000 | |||
Accounting Standards Update 2014-09 [Member] | |||||
Summary of Significant Accounting Policies [Line Items] | |||||
Increase in deferred revenue and accumulated deficit | $ 22,600,000 | ||||
Increased in revenue | 1,500,000 | ||||
Increase decrease in net income | $ 1,500,000 | ||||
Net income increased per share, basic diluted | $ / shares | $ 0.08 |
Share-based Compensation Plan_2
Share-based Compensation Plans - Additional Information (Detail) $ in Millions | 3 Months Ended | |
Sep. 30, 2018USD ($)Planshares | Sep. 30, 2017USD ($)shares | |
Share-Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Number of equity compensation plans | Plan | 2 | |
Stock options granted | 863,000 | 715,000 |
2013 Employee Stock Purchase Plan [Member] | ||
Share-Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Share based awards issued | 0 | |
Number of shares authorized | 128,571 | |
Employees and Non-Employee Directors [Member] | 2013 Equity and Incentive Plan [Member] | ||
Share-Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Stock options granted | 863,000 | |
Stock Options [Member] | ||
Share-Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Share-based compensation expense | $ | $ 1.2 | $ 1.5 |
Unrecognized compensation expense | $ | $ 7 |
Share-based Compensation Plan_3
Share-based Compensation Plans - Summary of Stock Option Activity (Detail) - $ / shares shares in Thousands | 3 Months Ended | |
Sep. 30, 2018 | Sep. 30, 2017 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||
Outstanding Beginning Balance, Shares | 3,107 | 2,714 |
Granted, Shares | 863 | 715 |
Exercised, Shares | (5) | |
Forfeited, Shares | (166) | (290) |
Expired, Shares | (9) | (4) |
Outstanding Ending Balance, Shares | 3,795 | 3,130 |
Exercisable, end of period, Shares | 2,092 | 1,691 |
Weighted average fair value of options granted during the period | $ 2.81 | $ 3.52 |
Outstanding Beginning Balance, Weighted Average Exercise Price | 10.93 | 12.96 |
Granted, Weighted Average Exercise Price | 4.31 | 4.88 |
Exercised, Weighted Average Exercise Price | 0.35 | |
Forfeited, Weighted Average Exercise Price | 8.08 | 9.98 |
Expired, Weighted Average Exercise Price | 14.95 | 17.80 |
Outstanding Ending Balance, Weighted Average Exercise Price | $ 9.54 | $ 11.40 |
Share-based Compensation Plan_4
Share-based Compensation Plans - Stock Option Pricing Model Assumption (Detail) | 3 Months Ended | |
Sep. 30, 2018 | Sep. 30, 2017 | |
Share-Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Dividend yield | 0.00% | 0.00% |
Expected term | 6 years 3 months | |
Risk-free interest rate, minimum | 2.77% | 1.83% |
Risk-free interest rate, maximum | 2.99% | 1.97% |
Expected Volatility | 69.22% | 83.53% |
Minimum [Member] | ||
Share-Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Expected term | 6 years | |
Maximum [Member] | ||
Share-Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Expected term | 6 years 3 months |
Investments - Summary of Compan
Investments - Summary of Company's Investments (Detail) - USD ($) $ in Thousands | Sep. 30, 2018 | Jun. 30, 2018 |
Investments - Current: | ||
Certificates of deposit | $ 1,869 | $ 2,106 |
Debt securities - held-to-maturity | 77,099 | 71,734 |
Total investments - current | $ 78,968 | $ 73,840 |
Investments - Summary of Comp_2
Investments - Summary of Company's Debt Securities Held-to-Maturity (Detail) - Investments - Current [Member] - USD ($) $ in Thousands | Sep. 30, 2018 | Jun. 30, 2018 |
Schedule of Held-to-maturity Securities [Line Items] | ||
Amortized Cost | $ 77,099 | $ 71,734 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (77) | (61) |
Fair Value | 77,022 | 71,673 |
US Government and Agencies Obligations [Member] | ||
Schedule of Held-to-maturity Securities [Line Items] | ||
Amortized Cost | 77,099 | 69,731 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (77) | (60) |
Fair Value | $ 77,022 | 69,671 |
Corporate Obligations [Member] | ||
Schedule of Held-to-maturity Securities [Line Items] | ||
Amortized Cost | 2,003 | |
Gross Unrealized Gains | 0 | |
Gross Unrealized Losses | (1) | |
Fair Value | $ 2,002 |
Investments - Summary of Amorti
Investments - Summary of Amortized Cost and Fair Value of Held-to-Maturity Debt Securities (Detail) $ in Thousands | Sep. 30, 2018USD ($) |
Investments Schedule [Abstract] | |
Amortized cost due in one year or less | $ 77,099 |
Total amortized cost | 77,099 |
Fair value due in one year or less | 77,022 |
Total fair value | $ 77,022 |
Fair Value of Financial Instr_3
Fair Value of Financial Instruments and Investments - Schedule of Major Category of Company's Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands | Sep. 30, 2018 | Jun. 30, 2018 |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, carrying value | $ 117,328 | $ 118,532 |
Fair Value on a Recurring Basis [Member] | ||
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 105,362 | 104,838 |
Assets, carrying value | 105,440 | 104,905 |
Fair Value on a Recurring Basis [Member] | Cash and Cash Equivalents [Member] | ||
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 26,472 | 31,065 |
Assets, carrying value | 26,472 | 31,065 |
Fair Value on a Recurring Basis [Member] | Certificate of Deposit [Member] | ||
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 1,868 | 2,100 |
Assets, carrying value | 1,869 | 2,106 |
Fair Value on a Recurring Basis [Member] | Corporate Obligations [Member] | ||
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 2,002 | |
Assets, carrying value | 2,003 | |
Fair Value on a Recurring Basis [Member] | US Government and Agencies Obligations [Member] | ||
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 77,022 | 69,671 |
Assets, carrying value | 77,099 | 69,731 |
Fair Value on a Recurring Basis [Member] | Quoted Prices in Active markets (Level 1) [Member] | ||
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 103,494 | 100,736 |
Fair Value on a Recurring Basis [Member] | Quoted Prices in Active markets (Level 1) [Member] | Cash and Cash Equivalents [Member] | ||
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 26,472 | 31,065 |
Fair Value on a Recurring Basis [Member] | Quoted Prices in Active markets (Level 1) [Member] | US Government and Agencies Obligations [Member] | ||
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 77,022 | 69,671 |
Fair Value on a Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member] | ||
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | 1,868 | 4,102 |
Fair Value on a Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member] | Certificate of Deposit [Member] | ||
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | $ 1,868 | 2,100 |
Fair Value on a Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member] | Corporate Obligations [Member] | ||
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets, fair value | $ 2,002 |
Collaboration Agreements - Addi
Collaboration Agreements - Additional Information (Detail) | Jul. 01, 2018USD ($) | Jul. 01, 2015TargetIndication | Jul. 31, 2018USD ($) | Apr. 30, 2018USD ($) | Jul. 31, 2015TargetIndication | Jun. 30, 2015USD ($)$ / sharesshares | Dec. 31, 2018USD ($) | Sep. 30, 2018USD ($)Programshares | Sep. 30, 2017USD ($) | Dec. 31, 2017USD ($) | Jun. 30, 2018USD ($)shares |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Common stock, shares issued | shares | 18,143,000 | 18,137,000 | |||||||||
Aggregate cash purchase price | $ 18,000 | $ 18,000 | |||||||||
Revenue | 14,034,000 | $ 10,315,000 | |||||||||
Account Receivables | 700,000 | $ 1,700,000 | |||||||||
Discovery Programs [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Decrease in transaction price | 1,800,000 | ||||||||||
Accounting Standards Update 2014-09 [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Increase in deferred revenue and accumulated deficit | $ 22,600,000 | ||||||||||
Additions to deferred revenue | 8,300,000 | ||||||||||
Milestone Revenue | 7,800,000 | ||||||||||
Deferred revenue recognized | 4,600,000 | ||||||||||
Milestone variable consideration | 1,100,000 | ||||||||||
Accounting Standards Update 2014-09 [Member] | XLRP [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Milestone Revenue | 10,000,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Number of target indications | TargetIndication | 3 | 3 | |||||||||
Non-refundable upfront fee paid | $ 94,000,000 | ||||||||||
Common stock, shares issued | shares | 1,453,957 | ||||||||||
Purchase price of common stock | $ / shares | $ 20.63 | ||||||||||
Aggregate cash purchase price | $ 30,000,000 | ||||||||||
Percentage common stock post-issuance | 8.10% | ||||||||||
Portion of upfront fee related to pre-funded activities | $ 58,400,000 | ||||||||||
Portion of upfront fee related to access of licenses | $ 35,600,000 | ||||||||||
Milestone Revenue | 112,300,000 | ||||||||||
Revenue | 14,025,000 | $ 10,308,000 | |||||||||
Decrease in transaction price | (1,100,000) | ||||||||||
Decrease in deferred revenue | (1,100,000) | ||||||||||
Deferred Revenue | 25,400,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | XLRS [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Milestone Revenue | 5,000,000 | $ 5,000,000 | |||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | XLRP [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Milestone Revenue | 2,500,000 | $ 2,500,000 | $ 10,000,000 | ||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | XLRP [Member] | Clinical Milestones [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Milestone Revenue | $ 10,000,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Accounting Standards Update 2014-09 [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Revenue | $ 4,700,000 | $ 1,100,000 | |||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Deferred revenue recognition estimated service period | 3 years | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | XLRS and XLRP [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Potential future milestone payments receivable | $ 472,500,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | XLRS [Member] | Clinical Milestones [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Potential future milestone payments receivable | 45,000,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | XLRS [Member] | Regulatory Approvals and First Commercial Sale in Specified Territories [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Potential future milestone payments receivable | 155,000,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | XLRS [Member] | Worldwide Sales Targets [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Potential future milestone payments receivable | 65,000,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | XLRP [Member] | Clinical Milestones [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Potential future milestone payments receivable | 42,500,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | XLRP [Member] | Regulatory Approvals and First Commercial Sale in Specified Territories [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Potential future milestone payments receivable | 102,500,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | XLRP [Member] | Worldwide Sales Targets [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Potential future milestone payments receivable | 62,500,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | Discovery Programs [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Potential future milestone payments receivable | 592,500,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | Category A Discovery Program [Member] | Clinical Milestones [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Potential future milestone payments receivable | 20,000,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | Category A Discovery Program [Member] | Regulatory Approvals and First Commercial Sale in Specified Territories [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Potential future milestone payments receivable | 70,000,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | Category B Discovery Program [Member] | Clinical Milestones [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Potential future milestone payments receivable | 27,500,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | Category B Discovery Program [Member] | Regulatory Approvals and First Commercial Sale in Specified Territories [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Potential future milestone payments receivable | 105,000,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | Category C Discovery Program [Member] | Clinical Milestones [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Potential future milestone payments receivable | 40,000,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Maximum [Member] | Category C Discovery Program [Member] | Regulatory Approvals and First Commercial Sale in Specified Territories [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Potential future milestone payments receivable | $ 140,000,000 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Minimum [Member] | Category A Discovery Program [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Number of programs | Program | 1 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Minimum [Member] | Category B Discovery Program [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Number of programs | Program | 1 | ||||||||||
Collaboration Agreement [Member] | BIOGEN [Member] | Minimum [Member] | Category C Discovery Program [Member] | |||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||
Number of programs | Program | 1 |
Collaboration Agreement - Summa
Collaboration Agreement - Summary of Performance Obligations and Transaction Price (Detail) - Collaboration Agreement [Member] - BIOGEN [Member] - Accounting Standards Update 2014-09 [Member] $ in Thousands | Sep. 30, 2018USD ($) |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |
Allocated Transaction Price | $ 112,330 |
XLRS [Member] | |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |
Allocated Transaction Price | 52,060 |
XLRP [Member] | |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |
Allocated Transaction Price | 43,570 |
Discovery Programs [Member] | |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |
Allocated Transaction Price | $ 16,700 |
Collaboration Agreement - Compo
Collaboration Agreement - Components of Collaboration Revenue (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Sep. 30, 2018 | Sep. 30, 2017 | |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
Total collaboration revenue | $ 14,034 | $ 10,315 |
Collaboration Agreement [Member] | BIOGEN [Member] | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
Total collaboration revenue | 14,025 | 10,308 |
Collaboration Agreement [Member] | BIOGEN [Member] | Licenses and Related Services [Member] | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
Total collaboration revenue | 4,619 | 9,754 |
Collaboration Agreement [Member] | BIOGEN [Member] | Development Services [Member] | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
Total collaboration revenue | 1,058 | $ 554 |
Collaboration Agreement [Member] | BIOGEN [Member] | Milestone Revenue [Member] | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
Total collaboration revenue | $ 8,348 |
Collaboration Agreements - Summ
Collaboration Agreements - Summary of Changes in Contract Assets and Liabilities (Detail) - Deferred Revenue [Member] $ in Thousands | 3 Months Ended |
Sep. 30, 2018USD ($) | |
Contract with Customer, Asset and Liability [Line Items] | |
Balance at Beginning of Period | $ 29,521 |
Additions | 10,000 |
Deductions | 14,096 |
Balance at End of Period | $ 25,425 |